GE Healthcare (NYSE:GE) announced that it will exclusively distribute the DyeVert portfolio for imaging technology developer Osprey Medical (ASX:OSP). Osprey’s DyeVert contrast minimization devices align with GE’s iodinated X-ray contrast media to offer a technology platform to address acute kidney injury (AKI) following interventional coronary angiograms in patients with chronic kidney disease (CKD), according to a news […]
Osprey Medical raises $7m, looks to raise $8m in entitlement offer
Osprey Medical (ASX:OSP) said today that it inked deals that could bring in up to $14.5 million for the company to support continued growth and accelerated commercialization of its product platform. The Minneapolis, Minn.-based company said it inked a $7 million private placement deal with investment management firm Allan Gray for approximately 64.5 million Chess Depository Interests, […]
Osprey Medical raises $18m
Osprey Medical (ASX:OSP) said today it raised $17.6 million (AUD $22.2 million) from an oversubscribed offering of Chess Depository Interests, and that it is looking to raise an additional $8.2 million (AUD $10.3 million) in an entitlement offer. The Australian company said it floated approximately 55.5 million CDIs, representing 27.7 million shares of common stock, at 32¢ […]
Firms in Minnesota’s Medical Alley raised $117m in Q3
Firms in Minnesota’s Medical Alley raised $117 million during the 3rd quarter, bringing their total year-to-date funding to $335.8 million, the trade group reported today. Medical Alley, which rebranded from LifeScience Alley in January, reported that 77 companies from the region completed funding rounds in 2016, matching 2015’s numbers between the 1st and 3rd quarters. “Medical Alley continues to […]
Osprey Medical raises $21.3m
Osprey Medical (ASX:OSP) said it raised $21.3 million (AUD $28 million) through the sale of CHESS depository interests to support the expanded commercialization of its DyVert System and ongoing research and development. The Australian company raised the funds from institutional investors through the sale of 100 million CDIs at 21¢ (AUD 28¢) per CDI, set […]
Osprey Medical dives on failed trial despite FDA wins
Australian investors, reacting today to news that Osprey Medical (ASX:OSP) failed to meet a key endpoint in a clinical trial, took OSP shares down by some -55% today. The plunge came despite news that the FDA approved expanded claims for Osprey’s Avert device, which is designed to reduce and monitor the amount of contrast agent injected […]
Osprey rises on FDA 510(k) for DyeVert
Osprey Medical (ASX:OSP) said it received FDA 510(k) clearance for its DyeVert contrast modulation system, sending shares of the company to a nearly 2-month high. The DyeVert system automates contrast modulation during manual dye injections, self adjusting for catheter and contrast types without requiring user adjustments, Osprey said. “With FDA Clearance of our DyeVert System, […]
Medtech investment in MN falls back to earth | Medtech funding for the week of April 20, 2015
Medtech investment in Minnesota falls back to earth
After an off-the-charts year in investment for 2014, the Minnesota bioscience industry has seen a more typical 1st quarter, according to a report from medtech lobby LifeScience Alley.
OSP fishes up $11m | Medtech funding for the week of March 23, 2015
Osprey Medical fishes up $11m private placement
